These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 15500555)

  • 1. A randomized trial of prolonged high dose of interferon plus ribavirin for hepatitis C patients nonresponders to interferon alone.
    Fattovich G; Zagni I; Ribero ML; Castagnetti E; Minola E; Lomonaco L; Scattolini C; Fabris P; Boccia S; Giusti M; Abbati G; Felder M; Rovere P; Redaelli A; Tonon A; Tomba A; Montanari R; Paternoster C; Distasi M; Fornaciari G; Tositti G; Rizzo C; Suppressa S; Pantalena M; Noventa F; Tagger A
    J Viral Hepat; 2004 Nov; 11(6):543-51. PubMed ID: 15500555
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A randomized trial to assess the efficacy of interferon alpha in combination with ribavirin in the treatment of interferon alpha nonresponders with chronic hepatitis C: superior efficacy of high daily dosage of interferon alpha in genotype 1.
    Tassopoulos NC; Tsantoulas D; Raptopoulou M; Vassiliadis T; Kanatakis S; Paraskevas E; Vafiadis I; Avgerinos A; Tzathas C; Manolakopoulos S; Ketikoglou I; Aggelis P; Goritsas K; Giannoulis G; Hatzis G G; Thomopoulos K; Akriviadis E; Sypsa V; Hatzakis A
    J Viral Hepat; 2003 May; 10(3):189-96. PubMed ID: 12753337
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reinforced interferon alpha-2b and ribavirin is more effective than standard combination therapy in the retreatment of chronic hepatitis C previously nonresponsive to interferon: a randomized trial.
    Poynard T; Marcellin P; Bissery A; Myers RP; Moussalli J; Degos F; Dhumeaux D; Riachi G; Bronowicki JP; Brissot P; Buffet C; Serfaty L; Naveau S; Sogni P; Beaugrand M; Gayno S; Larrey D; Samuel D; Eugene C; Pol S; Bedossa P; Daurat V; Chaumet-Riffaud P;
    J Viral Hepat; 2003 May; 10(3):197-204. PubMed ID: 12753338
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Response of hepatitis C genotype-4 naïve patients to 24 weeks of Peg-interferon-alpha2b/ribavirin or induction-dose interferon-alpha2b/ribavirin/amantadine: a non-randomized controlled study.
    El-Zayadi AR; Attia M; Barakat EM; Badran HM; Hamdy H; El-Tawil A; El-Nakeeb A; Selim O; Saied A
    Am J Gastroenterol; 2005 Nov; 100(11):2447-52. PubMed ID: 16279899
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of prolonged 5 million units of interferon in combination with ribavirin for relapser patients with chronic hepatitis C.
    Fattovich G; Zagni I; Fornaciari G; Minola E; Fabris P; Boccia S; Giusti M; Abbati G; Felder M; Rovere P; Redaelli A; Tonon A; Montanari R; Paternoster C; Distasi M; Castagnetti E; Tositti G; Rizzo C; Suppressa S; Pantalena M; Lomonaco L; Scattolini C; Tagger A
    J Viral Hepat; 2003 Mar; 10(2):111-7. PubMed ID: 12614467
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment effects and predictors of a 24-week course of interferon alpha-2b plus ribavirin combination therapy for patients with chronic hepatitis C.
    Tomimatsu M; Aizawa Y; Chuganji Y; Ishizuka H; Fujita Y; Aizawa R; Abe H; Matsuda T; Itou Y; Nakanishi H; Ushiyama H; Higuchi T; Fujimoto T; Endou H; Iga D; Ohta K; Kuroda H
    J Gastroenterol Hepatol; 2006 Jul; 21(7):1177-83. PubMed ID: 16824072
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pegylated interferon alfa-2b plus ribavirin in the retreatment of interferon-ribavirin nonresponder patients.
    Taliani G; Gemignani G; Ferrari C; Aceti A; Bartolozzi D; Blanc PL; Capanni M; Esperti F; Forte P; Guadagnino V; Mari T; Marino N; Milani S; Pasquazzi C; Rosina F; Tacconi D; Toti M; Zignego AL; Messerini L; Stroffolini T;
    Gastroenterology; 2006 Apr; 130(4):1098-106. PubMed ID: 16618404
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of interferon alpha-2b induction therapy before retreatment for chronic hepatitis C.
    Carr C; Hollinger FB; Yoffe B; Wakil A; Phillips J; Bzowej N; Leung J; Mirro K; Poordad F; Moore DH; Gish RG
    Liver Int; 2007 Oct; 27(8):1111-8. PubMed ID: 17845540
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Daily dose of interferon alpha-2b and ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection: a randomised controlled study.
    Benetti G; Borzio M; Ramella G; Bellati G; Fargion S; Colombo A; Croce G; Iamoletti C; Balzola F; Rizzetto M;
    Intern Emerg Med; 2006; 1(2):113-8. PubMed ID: 17111783
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Early viral kinetics and treatment outcome in combination of high-dose interferon induction vs. pegylated interferon plus ribavirin for naive patients infected with hepatitis C virus of genotype 1b and high viral load.
    Tsubota A; Arase Y; Someya T; Suzuki Y; Suzuki F; Saitoh S; Ikeda K; Akuta N; Hosaka T; Kobayashi M; Kumada H
    J Med Virol; 2005 Jan; 75(1):27-34. PubMed ID: 15543591
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High-dose interferon alpha-2b induction therapy in combination with ribavirin for Japanese patients infected with hepatitis C virus genotype 1b with a high baseline viral load.
    Tsubota A; Arase Y; Suzuki F; Suzuki Y; Akuta N; Hosaka T; Someya T; Kobayashi M; Saitoh S; Ikeda K; Kumada H
    J Gastroenterol; 2004; 39(2):155-61. PubMed ID: 15069622
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Daily interferon induction regimen using different manufactured interferons (alpha-2A or alpha-2B) in combination with ribavirin for treatment of chronic hepatitis C: a prospective randomized study.
    Braga EL; Lyra AC; Nascimento L; Netto E; Kalabrik L; Lyra LG
    Arq Gastroenterol; 2006; 43(4):275-9. PubMed ID: 17406754
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A randomized 4-arm multicenter study of interferon alfa-2b plus ribavirin in the treatment of patients with chronic hepatitis C not responding to interferon alone.
    Saracco G; Ciancio A; Olivero A; Smedile A; Roffi L; Croce G; Colletta C; Cariti G; Andreoni M; Biglino A; Calleri G; Maggi G; Tappero GF; Orsi PG; Terreni N; Macor A; Di Napoli A; Rinaldi E; Ciccone G; Rizzetto M
    Hepatology; 2001 Jul; 34(1):133-8. PubMed ID: 11431744
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Effect of ribavirin on dynamics of hepatitis C viremia in interferon alpha-treated patiens with response or no response].
    Berg T; Kaul T; Naumann U; Wiedenmann B; Hopf U
    Z Gastroenterol; 2000 Nov; 38(11):881-6. PubMed ID: 11132533
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Early HCV RNA changes in patients with chronic hepatitis C treated with peginterferon alfa 2b and ribavirin.
    Gallegos-Orozco JF; Fuentes AP; Olivera-Martinez MA; Gutiérrez-Reyes G; Cortina D; Oregel JA; Pérez-Pruna C; Sixtos MS; Cruz-Castellanos S; Soto-Ramírez LE; Rodríguez-Díaz R; Fuentes-Romero L; Gutiérrez-Ruiz MC; Kershenobich D
    Rev Invest Clin; 2003; 55(2):138-42. PubMed ID: 12827916
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomized trial of pegylated interferon alpha-2b plus ribavirin in the retreatment of chronic hepatitis C.
    Jacobson IM; Gonzalez SA; Ahmed F; Lebovics E; Min AD; Bodenheimer HC; Esposito SP; Brown RS; Bräu N; Klion FM; Tobias H; Bini EJ; Brodsky N; Cerulli MA; Aytaman A; Gardner PW; Geders JM; Spivack JE; Rahmin MG; Berman DH; Ehrlich J; Russo MW; Chait M; Rovner D; Edlin BR
    Am J Gastroenterol; 2005 Nov; 100(11):2453-62. PubMed ID: 16279900
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of low-dose pegylated interferon versus standard high-dose pegylated interferon in combination with ribavirin in patients with chronic hepatitis C with genotype 3: an Indian experience.
    Sood A; Midha V; Hissar S; Kumar M; Suneetha PV; Bansal M; Sood N; Sakhuja P; Sarin SK
    J Gastroenterol Hepatol; 2008 Feb; 23(2):203-7. PubMed ID: 17645472
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A randomized trial to assess the efficacy of interferon-alpha daily in combination with ribavirin in the treatment of naïve patients with chronic hepatitis C.
    Tassopoulos NC; Ketikoglou I; Tsantoulas D; Raptopoulou M; Hatzis G; Vafiadis I; Sidiropoulos L; Kanatakis S; Anagnostopoulos G; Sypsa V; Hatzakis A;
    J Viral Hepat; 2003 Sep; 10(5):383-9. PubMed ID: 12969190
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Peginterferon alfa-2b plus ribavirin for naïve patients with genotype 1 chronic hepatitis C: a randomized controlled trial.
    Bruno S; Cammà C; Di Marco V; Rumi M; Vinci M; Camozzi M; Rebucci C; Di Bona D; Colombo M; Craxì A; Mondelli MU; Pinzello G
    J Hepatol; 2004 Sep; 41(3):474-81. PubMed ID: 15336451
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of adherence to therapy on sustained response in daily or three times a week interferon alpha-2b plus ribavirin treatment of naive and nonresponder chronic hepatitis C patients.
    Raptopoulou M; Tsantoulas D; Vafiadi I; Ketikoglou I; Paraskevas E; Vassiliadis T; Kanatakis S; Hatzis G; Sidiropoulos L; Akriviadis E
    J Viral Hepat; 2005 Jan; 12(1):91-5. PubMed ID: 15655054
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.